Super Probiotics: Intestinal Knight engineered bacteria beat IBD

According to legend, in an ancient village, some villagers have a rare disease, often diarrhea, abdominal pain, blood in the stool, searching for doctors can not be cured.

One day, the two siblings Xixi and Beibei accidentally picked up a rare medical book in a cave, which recorded this disease: Inflammatory bowel disease (IBD), an inflammatory disease that mainly involves the digestive tract...

To treat this disease, it is necessary to synthesize the two magic weapon "plasmid" and "Escherichia coli" stored at the bottom of the Big Wild Goose Pagoda, summon the intestinal knight - engineering E. coli, and take the antidote it gives to heal.

Brother and sister to resolutely decided to save the villagers, they through the steep mountains, trek through the dense forest, and finally came to the Big Wild Goose Pagoda.

At the base of the Big Wild Goose Pagoda is a huge maze that hides the secrets of engineering E. coli. They supported each other and worked together to solve the puzzles in the maze.

Finally, under the guidance of the medical book, the siblings introduced the plasmid into the E. coli, successfully summoned the intestinal Knight engineering bacteria.

They happily took the antidote back to the village, applied it to the villagers with IBD, and the miracle drug worked so well that the villagers recovered one by one. The whole village is full of joy and gratitude, and Xixi and Beibei are regarded as little heroes by the villagers.

Inflammatory bowel disease (IBD)

Inflammatory bowel disease (IBD) is an inflammatory disease that primarily affects the digestive tract, including Crohn's Disease (CD) and Ulcerative colitis (UC). At the turn of the 21st century, IBD has become a global disease with rising prevalence in the newly industrialized countries of Asia, South America, and the Middle East. In China, the incidence of IBD has risen along with economic development and lifestyle changes, resulting in a substantial increase in the disease burden. From 1990 to 2019, the incidence of IBD in China increased from 1.45/100,000 to 3.62/100,000, with an overall increase of 14.97%. The age-standardized incidence increased from 1.47 per 100,000 to 3.01 per 100,000, with an overall increase of 10.48%[1].

The disease burden of IBD is rising globally, seriously affecting patients' quality of life and work productivity, while also attracting widespread attention from the medical community. The main purpose of its treatment is to reduce inflammatory activity, maintain remission, and reduce the recurrence rate and surgical rate[2]. IBD is a lifelong disease that requires treatment, and there is no effective cure, and current treatment drugs are more like opening "mystery boxes".

In order to give more such IBD patients a lighthouse, so that they can go out into the sunlight and reveal to the outside world that I am an IBD patient, and work and live in a big way. We use synthetic biology to genetically engineering E. coli to treat IBD. Compared to other methods, our engineered probiotics have the advantages of being safe, harmless, inexpensive and household. By harnessing the power of the gut microbiome to help patients with IBD and improve their quality of daily life, we hope to address the lack of targeted treatment options and reduce treatment costs.


  1. [1]包云丽,汪哲,唐海茹,等 . 1990—2019 年中国炎症性肠病疾病负担及变化趋势分析[J]. 中国 全科医学,2023.
  2. [2]陈晓芬,陈钰涵,马娟 . 炎症性肠病新型治疗方法的研究进展[J]. 中国全科医学,2023,26(27): 3349-3354.
  3. [3]Laura E. Targownik, MD, MSHS and others, Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease,Inflammatory Bowel Diseases, Volume 20, Issue 4, 1 April 2014, Pages 622–630
  4. [4]Nature Clinical Practice Gastroenterology & Hepatology volume 4, pages78–91 (2007)
  5. [5]Targownik LE, Nugent Z, Singh H, Bernstein CN. Prevalence of and outcomes associated with corticosteroid prescription in inflammatory bowel disease. Inflamm Bowel Dis. 2014 Apr;20(4):622-30.
  6. [6]倪欣, 黄坤, 马俊杰. Procaspase-3 小分子激活剂的研究进展[J]. 中国现代应用药学, 2019, 36(3): 368-371.
  7. [7]Bai AP, Ouyang Q. Probiotics and inflammatory bowel diseases. Postgrad Med J. 2006 Jun;82(968):376-82.